Posts by tag
precision oncology
Two Nervous Systems, One Room: Practicing a New Kind of Intelligence in Oncology
Over the past year, I have found myself returning to one question with increasing insistence: when a patient walks through the door of an oncology clinic, who, exactly, has walked in? The obvious answer is a person with cancer. We…
Time is of Essence
Europe has never had more powerful tools against cancer. But progress means little if patients cannot reach them in time. Cancer has never moved at the speed of bureaucracy. Today, science can identify molecular alterations that were once invisible. Biomarker…
CancerWorld | PICI– Special Issue 2026
10 Years of PICI: From Discovery to Impact Ten years ago, the Parker Institute for Cancer Immunotherapy (PICI) was created around a bold premise: that progress in cancer research could be accelerated by changing not only what science pursued, but…
The Patient’s Voice May Be One of Oncology’s Best Prognostic Tools
Large meta-analysis suggests patient-reported outcomes complement traditional clinical assessment. Despite advances in imaging, molecular profiling, and biomarkers, accurately estimating how long a patient with cancer is likely to survive remains challenging. Now, a large analysis involving data from more than…
Could GLP-1 Drugs Slow Cancer Spread? New Study Offers Encouraging Clues
Treatment with GLP-1 receptor agonists (GLP-1RAs) was associated with a significantly lower risk of progression to metastatic disease in non–small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). The study, presented at the 2026 American…
Behind Every Drug There Is a Story: Brian Druker, Imatinib, and the Human Journey Behind a Revolution in Cancer Care
Twenty-five years after imatinib transformed chronic myeloid leukaemia from a fatal diagnosis into a manageable disease for many patients, Brian Druker reflects on the curiosity, setbacks, and patients who shaped one of oncology's greatest breakthroughs. Long before I understood the…
When RAS Becomes Treatable: Eileen O’Reilly on daraxonrasib in Pancreatic Cancer
Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…
Daraxonrasib: A Turning Point for Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…
The Ovation and the Asterisk
Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…
Building Beyond the Bedside: Dr Mohamed Emam Sobeih’s Vision for the Future of Oncology
From crowded oncology wards in Cairo to international leadership in cancer education, Dr. Mohamed Emam Sobeih has built a career shaped by one central belief: treating cancer requires more than medicine alone. At the National Cancer Institute Egypt, where Dr…